Ipamorelin and CJC-1295 — research guide cover image
Research Guide

Ipamorelin and CJC-1295: A Research Overview

Ipamorelin and CJC-1295 are studied together because they stimulate the same output through two entirely separate receptors. Understanding why that combination is mechanistically interesting requires separating the two pathways.

Two Routes to One Output

Growth hormone release from pituitary somatotrophs is regulated by two distinct stimulatory inputs. Growth hormone-releasing hormone acts at the GHRH receptor. Ghrelin acts at the growth hormone secretagogue receptor, GHS-R1a. Both are G protein-coupled receptors, but they are different proteins using different signaling routes — GHRH through cyclic AMP, GHS-R1a through phospholipase C and calcium mobilisation.

A third input, somatostatin, is inhibitory. The net output reflects the balance of all three.

Ipamorelin

Ipamorelin is a synthetic pentapeptide acting as a selective agonist at GHS-R1a. Selectivity is its defining characteristic: earlier growth hormone secretagogues produced measurable effects on cortisol and prolactin, whereas ipamorelin has been reported to have comparatively little effect on these in model systems.

That selectivity is what makes it useful as a research tool. A compound that stimulates growth hormone release without substantially perturbing other pituitary outputs allows the somatotropic axis to be studied with fewer confounding variables.

CJC-1295 Without DAC

CJC-1295 without DAC, also called modified GRF(1-29), is a GHRH analog based on the same 1-29 fragment as sermorelin, carrying four amino acid substitutions that increase resistance to DPP-4 cleavage and improve stability.

The “without DAC” distinction matters. The DAC version incorporates a drug affinity complex that binds albumin and extends half-life to a much greater degree, producing sustained elevation. The non-DAC version has a shorter duration, which preserves a more pulsatile release pattern in model systems. Since pulsatility is itself a subject of study in somatotropic research, the two versions are not interchangeable.

Why the Combination Is Studied

Because the two act at separate receptors with separate signaling cascades, combined exposure allows researchers to ask whether the effect is additive or synergistic. Combined preparations are commonly supplied as an even split — 5mg CJC-1295 without DAC and 5mg ipamorelin, 10mg per vial. Published work in this area has examined whether simultaneous stimulation produces a greater response than either alone, and whether the pulsatile character of release is preserved or altered.

There is also a mechanistic rationale beyond simple addition: ghrelin receptor agonism has been reported to reduce somatostatin tone in some models, which would amplify the effect of concurrent GHRH stimulation. Whether this holds consistently remains a research question.

Areas of Scientific Investigation

Applications include GHS-R1a and GHRH receptor pharmacology, dual-pathway stimulation studies, pulsatile secretion dynamics, secretagogue selectivity comparisons, and work distinguishing receptor-level from feedback-level effects.

Why Purity and Verification Matter

Reproducibility in peptide research depends on knowing exactly what is in the vial. Sequence-related impurities, truncated fragments and residual synthesis reagents can all influence experimental outcomes, and two preparations nominally of the same compound can behave differently if purity differs. Independent HPLC and mass spectrometry testing establishes both identity and purity, which is why third-party verification is standard practice for research-grade material. All compounds referenced here are supplied as lyophilized powder at 99%+ purity with independent verification.

Summary

Ipamorelin is a selective ghrelin receptor agonist; CJC-1295 without DAC is a stabilised GHRH analog. They converge on the same output through separate receptors, which is why combined preparations are used to study additive and synergistic effects on the somatotropic axis. Both are intended strictly for laboratory research.

Related Research Peptides

Ipamorelin 10mg · CJC-1295 + Ipamorelin 10mg · Sermorelin 10mg · Tesamorelin 5mg · Tesamorelin 10mg

For laboratory and research use only. Not for human or veterinary use, and not for diagnostic or therapeutic purposes.

Research material: CJC-1295 in every vial size (5mg) · Ipamorelin in every vial size (5mg–10mg)

Leave a Reply

Your email address will not be published. Required fields are marked *

Cart0
×

Research updates from Santa Cruz Peptides

New compounds, restocks and research guides — straight to your inbox.

For laboratory and research use only. Unsubscribe anytime.
Free Shipping On All Orders!